• Per Sandberg, appointed by Sandberg Development AB,
• Max Mitteregger, appointed by Gladiator,
• Arne Lööw, appointed by Fjärde AP-fonden, and
• Per Olof Wallström, Chairman of the Board

The Nomination Committee's proposals will be presented in the Notice to the AGM 2022 and on Camurus' website, www.camurus.com.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company's address, Ideon Science Park, SE-223 70, Lund, Sweden. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 10 February 2022, to ensure that the proposals can be adequately considered by the Nomination Committee.

The AGM 2022 in Camurus will be held at 5:00 pm CET on 12 May 2022 in Lund. Shareholders who want to have a matter addressed at the AGM 2022 must submit such a proposal to the same address as above (subject "Annual General Meeting 2022") by 24 March 2022 at the latest.

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20
p.o.wallstrom@telia.com

The information was submitted for publication at 07:00 am CET on 27 October 2021.